Brief: Eagle Pharmaceuticals Enters Into Limited Waiver And First Amendment To Third Amended And Restated Credit Agreement
16/01/2024 12:20
Jan 16 (Reuters) - Eagle Pharmaceuticals Inc EGRX.O :
* EAGLE PHARMACEUTICALS - ON JAN 12, CO ENTERED INTO LIMITED
WAIVER AND FIRST AMENDMENT TO THIRD AMENDED AND RESTATED CREDIT
AGREEMENT
* EAGLE PHARMACEUTICALS- UNDER TERMS, UNTIL CO SATISFIES
FINANCIAL
REQUIREMENT, AVAILABILITY UNDER AMENDED AGREEMENT TO BE REDUCED
TO $50 MILLION
Further company coverage: EGRX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Eagle Pharmaceuticals
See all newsDoes a common heart attack pill help everyone? Studies disagree
Brief: Eagle Pharmaceuticals Says Continuing To Evaluate Its Internal Control Over Financial Reporting
Brief: Nantahala Capital Management, Llc Reports 15.1% Passive Stake In Eagle Pharmaceuticals Inc As Of June 30- SEC Filing
Brief: Eagle Pharmaceuticals Says On May 28, Co Requested Hearing Before Hearings Panel Of Nasdaq, Following Delisting Notice From Nasdaq - SEC Filing
Brief: Eagle Pharmaceuticals Announces Receipt Of Delisting Notification From Nasdaq